Biogen proposes to buy Sage’s remaining stake in a $442 million deal

Biogen is navigating the slow pace of sales of its Alzheimer’s drug Lacambi in the United States after concerns about its cost, effectiveness and side effects. Sage, whose shares fell 74.9 percent last year, abandoned development of its drug dalzenemdor after multiple trial failures.